New research published online in The FASEB Journal suggests that a novel therapeutic target called LPCAT2 may prove effective against pain that is not receptive to the current treatments. This study ...

Vertex is set to move a small-molecule inhibitor of voltage-gated sodium channel 1.8 (Nav1.8) into phase III trials in acute pain by the end of the year. This positions VX-548 as one of the most ...

SHANGHAI, June 19, 2018 /PRNewswire/ -- June 19, 2018, Luye Pharma Group announced that clinical applications of the company's new compound candidate, extended release tablets (''LY03012''), a China ...

SAN FRANCISCO--(BUSINESS WIRE)--Concentric Analgesics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel, non-opioid pain therapeutics, today announced ...

SAN FRANCISCO--(BUSINESS WIRE)--Concentric Analgesics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel, non-opioid pain therapeutics, today announced ...

SBS-1000 was shown to be safe and well tolerated in healthy volunteers in this Phase 1 Single Ascending Dose (SAD) study No serious adverse events observed Sedation at higher doses proved the dose ...